No Data
No Data
Recce Pharmaceuticals Secures Approval for Diabetic Food Infection Clinical Trial in Indonesia; Shares Rise 5%
Recce Pharmaceuticals Advances Phase 3 Trial in Indonesia
Recce Pharmaceuticals Ready for Phase 3 Clinical Trial of R327G in Diabetic Foot Infections in Indonesia | ASX:RCE, OTC:RECEF
Investors in Recce Pharmaceuticals (ASX:RCE) Have Seen Notable Returns of 68% Over the Past Five Years
Recce Pharmaceuticals Secures Australian Patent for Anti-infectives; Covered in All Major Markets
Complete Patent Protection for 2 Recce Anti-infective Treatments